STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The SINNR study will evaluate the virologic efficacy (viral load <50 copies/mL)and safety of
STRIBILD administered for 48 weeks to HIV-infected current or recent illicit drug users.
Details
Lead Sponsor:
Vancouver Infectious Diseases Centre
Collaborators:
Gilead Sciences Regina General Hospital
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination